logo
Twitter
Discord
Email
logo
Intuitive Surgical, Inc.

Intuitive Surgical, Inc.

NASDAQ•ISRG
CEO: Dr. Gary S. Guthart Ph.D.
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2000-06-16
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Contact Information
1020 Kifer Road, Sunnyvale, CA, 94086-5304, United States
408-523-2100
www.intuitive.com
Market Cap
$193.78B
P/E (TTM)
70.4
76.8
Dividend Yield
--
52W High
$616.00
52W Low
$425.00
52W Range
61%
Rank31Top 15.1%
5.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$2.51B+22.91%
4-Quarter Trend

EPS

$1.98+24.53%
4-Quarter Trend

FCF

$735.60M+60.40%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Total revenue $7.20B for nine months, reflecting 21% growth versus prior period, driven by product sales.
Net Income Surges Net income attributable $2.06B for nine months, marking strong 26% increase compared to the prior year period.
Procedure Volume Rises da Vinci procedures reached 2.68M total for nine months, showing 18% volume increase across US and OUS.
Ion Adoption Accelerates Ion system placements totaled 153 units for nine months, reflecting 54% procedure volume growth year-to-date.

Risk Factors

Gross Margin Compression Gross profit margin fell to 65% for nine months, down from 67% last year due to cost pressures.
Tariff Cost Impact Tariffs increased Cost of Revenue by $37M for nine months ended September 2025, impacting profitability.
Litigation Exposure Unresolved Product liability lawsuits remain unresolved; management cannot estimate potential loss exceeding current accruals.
Macroeconomic Headwinds Persist Liquidity risks exist from inflation, elevated interest rates, and ongoing supply chain challenges globally.

Outlook

Da Vinci 5 System Launch Phased launch of next-generation da Vinci 5 system continues across OUS markets, driving ASP increase.
European Distribution Acquisition Pending acquisition of European distribution businesses requires upfront cash payment of approximately EUR 290M.
Capital Investment Planned Expect $625M to $675M capital expenditures for 2025, primarily funding facilities expansion and vertical integration.
R&D Investment Increasing Research and development expenses increased 13% year-to-date, expected to continue rising for platform initiatives.

Peer Comparison

Revenue (TTM)

Becton, Dickinson and CompanyBDX
$21.84B
+8.2%
Baxter International Inc.BAX
$11.02B
-6.3%
Intuitive Surgical, Inc.ISRG
$9.61B
+22.2%

Gross Margin (Latest Quarter)

Intuitive Surgical, Inc.ISRG
66.4%
-1.1pp
ResMed Inc.RMD
61.5%
+2.9pp
The Cooper Companies, Inc.COO
61.1%
-5.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ISRG$193.78B70.416.1%0.0%
BDX$57.59B34.36.6%34.7%
RMD$36.97B25.725.1%10.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.2%
Moderate Growth
4Q Net Income CAGR
0.9%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Jan 22, 2026
|
EPS:$2.25
|
Revenue:$2.72B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 22, 2025|
    Revenue: $2.51B+22.9%
    |
    EPS: $1.98+24.5%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 23, 2025|
    Revenue: $2.44B+21.4%
    |
    EPS: $1.84+24.3%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 23, 2025|
    Revenue: $2.25B+19.2%
    |
    EPS: $1.95+26.6%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Jan 31, 2025|
    Revenue: $8.35B+17.2%
    |
    EPS: $6.54+27.7%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 18, 2024|
    Revenue: $2.04B+16.9%
    |
    EPS: $1.59+34.7%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 19, 2024|
    Revenue: $2.01B+14.5%
    |
    EPS: $1.48+23.3%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 19, 2024|
    Revenue: $1.89B+11.5%
    |
    EPS: $1.54+52.5%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Jan 31, 2024|
    Revenue: $7.12B+14.5%
    |
    EPS: $5.12+37.6%
    Beat